Patent ID: 7747389

Claim:
A method of predicting recurrence of hepatocellular carcinoma (HCC) in a human subject having HCC, comprising: a) obtaining a HCC sample from the human subject, for whom prediction of recurrence of HCC is to be made; b) determining expression levels of at least ten genes indicative of recurrence of HCC, wherein the at least ten genes indicative of recurrence of HCC are selected from the group consisting of: (1) platelet-derived growth factor receptor alpha, (2) tumor necrosis factor alpha inducible protein A20, (3) lysosomal-associated multitransmembrane protein (LAPTm5), (4) HLA-DR alpha heavy chain, (5) rel proto-oncogene, (6) Staf50, (7) putative serine/threonine protein kinase, (8) MADS/MEF2-family transcription factor (MEF2C), (9) HUMLUCA 19 Human cosmid clone LUCA 19 from 3p21.3, (10) DEAD-box protein p72, (11) vimentin, and (12) KIAK0002 each as set forth in Table 2; c) comparing the expression levels of the at least ten genes to expression levels of the same set of genes from HCC samples obtained from human patients with recurrence of HCC and/or from HCC samples obtained from human patients without recurrence of HCC, thereby determining the likelihood of recurrence of HCC in the human subject having HCC.